We analyzed more than 300 biomarkers in two multicenter, observational clinical trials including more than 1,200 patients across 37 sites, many of whom experienced sepsis, shock, major surgery and trauma.4 Two biomarkers stood out for assessing the risk of acute kidney injury development: TIMP-2 and IGFBP-7.

Map showing where clinical trials took place

When can AKI intervention begin?

The NephroCheck Test and AKIRisk Score can help Dr. Harold Szerlip decide when to intervene earlier with patients at risk of developing acute kidney injury in order to try to prevent progression to kidney damage.